Andrew Robbins is the founder of Cogent Biosciences. Cogent Biosciences has raised $104M in total funding. Latest round: Series A. Based in Waltham, MA.
Andrew Robbins is the President and CEO of Cogent Biosciences, a biotechnology company focused on developing treatments for liver diseases. He has served as the company's chief executive since at least March 2021 and is known for leading the company through clinical development and insider stock transactions.
Full founder directory · Investor directory · Company funding database · Fundraising library